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Circulating lipopolysaccharide (LPS) concentrations are often elevated in patients with sep-
sis or with various endogenous diseases that are associated with metabolic endotoxemia.
Involuntary loss of skeletal muscle, termed muscle wasting, is commonly observed in these
conditions, suggesting that circulating LPS might play an essential role in its development.
Although impairment of muscle regeneration is an important determinant of skeletal muscle
wasting, it is unclear whether LPS affects this process and, if so, by what mechanism. Here,
we used the C2C12 myoblast cell line to investigate the effects of LPS on myogenesis.
Methods
C2C12 myoblasts were grown to 80% confluence and induced to differentiate in the
absence or presence of LPS (0.1 or 1 μg/mL); TAK-242 (1 μM), a specific inhibitor of Toll-
like receptor 4 (TLR4) signaling; and a tumor necrosis factor (TNF)-α neutralizing antibody
(5 μg/mL). Expression of a skeletal muscle differentiation marker (myosin heavy chain II),
two essential myogenic regulatory factors (myogenin and MyoD), and a muscle negative
regulatory factor (myostatin) was analyzed by western blotting. Nuclear factor-κB (NF-κB)
DNA-binding activity was measured using an enzyme-linked immunosorbent assay.
Results
LPS dose-dependently and significantly decreased the formation of multinucleated myo-
tubes and the expression of myosin heavy chain II, myogenin, and MyoD, and increased
NF-κB DNA-binding activity and myostatin expression. The inhibitory effect of LPS on myo-
genic differentiation was reversible, suggesting that it was not caused by nonspecific toxic-
ity. Both TAK-242 and anti-TNF-α reduced the LPS-induced increase in NF-κB DNA-binding
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activity, downregulation of myogenic regulatory factors, and upregulation of myostatin,
thereby partially rescuing the impairment of myogenesis.
Conclusions
Our data suggest that LPS inhibits myogenic differentiation via a TLR4–NF-κB-dependent
pathway and an autocrine/paracrine TNF-α-induced pathway. These pathways may be
involved in the development of muscle wasting caused by sepsis or metabolic endotoxemia.
Introduction
Lipopolysaccharide (LPS), the major molecular component of the outer membrane of gram-
negative bacteria, binds to Toll-like receptor 4 (TLR4) and induces formation of a TLR4–
CD14 complex that increases nuclear factor-κB (NF-κB) activity [1,2]. LPS can cause a dysre-
gulated inflammatory response leading to life-threatening organ dysfunction; a syndrome
termed sepsis [3]. Increased levels of circulatory LPS are observed in patients with sepsis [4],
elderly subjects [5,6] and individuals with diabetes mellitus [7], obesity [7], human immuno-
deficiency virus infection [8,9], cancer [10,11], liver cirrhosis [12], and end-stage kidney dis-
ease [13,14]. In the latter cases, increased LPS levels are caused by bacterial translocation from
the intestinal tract to the circulation [15], a phenomenon known as metabolic endotoxemia
[15]. Severe involuntary loss of skeletal muscle, termed muscle wasting, can be observed in all
of these conditions [16], suggesting a potential role for circulating LPS in its development.
Muscle wasting contributes to generalized weakness and debilitation, worsens quality of life,
and increases mortality and economic burden [17]. Thus, there is an urgent need to advance
our knowledge of its molecular pathogenesis.
One important cause of muscle wasting is breakdown of muscle protein through the ubi-
quitin–proteasome-dependent pathway [18]. Previous studies have shown that LPS activates
the ubiquitin–proteasome pathway through TLR4 and induces catabolism both in cultured
C2C12 muscle cells [19] and in rat muscle in vivo [20]. In agreement with these findings,
increased ubiquitin–proteasome activity has been reported in elderly subjects [21] and in
patients with metabolic endotoxemia due to diabetes mellitus [22], obesity [23], liver cirrhosis
[24], and chronic kidney disease [25,26]. Damaged or degenerated myofibers are repaired or
replaced through myogenesis, the process by which myoblasts fuse to form multinucleated
myotubes. Although reduced myogenic capacity is another important determinant of skeletal
muscle wasting [27–31], it is not known whether LPS affects this process.
Vertebrate skeletal muscle myogenesis is under the strict control of muscle-specific tran-
scription factors such as MyoD and myogenin [32,33] and negative regulatory factors such as
myostatin [34–36]. Previous work with cultured C2C12 myoblasts suggests that exogenous
tumor necrosis factor α (TNF-α) inhibits myoblast differentiation by downregulating myo-
genin and MyoD via NF-κB activation [27–31]. Hyperammonemia [37] and reactive oxygen
species [38] also act through NF-κB to induce myostatin expression in mouse myoblasts.
Whether and how LPS affects myogenesis regulatory factors is unknown. Since TLR4 is
expressed in skeletal muscle [39–41] and circulating LPS can reach peripheral tissues [42], we
hypothesized that LPS might perturb both positive and negative regulatory factors via TLR4–
NF-κB signaling in differentiating myoblasts, thereby suppressing muscle regeneration.
LPS stimulates expression of proinflammatory cytokines, including TNF-α, not only in
classical immune tissues but also in skeletal muscle [40,41,43]. Since TNF-α contributes to
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many pathogenic processes, including insulin resistance [44,45] and carcinogenesis [46],
through both autocrine and paracrine mechanisms, it is possible that LPS-induced TNF-α
secretion by myoblasts might also play a role in muscle wasting.
Here, we aimed to evaluate the effect of LPS on myogenesis, including the possible roles
of TLR4–NF-κB signaling and autocrine/paracrine TNF-α on both positive and negative
muscle regulatory factors. We found that selective inhibition of TLR4 signaling or neutraliza-
tion of TNF-α activity had a beneficial effect on LPS-treated C2C12 myoblasts. Thus, TLR4–




The murine C2C12 myoblast cell line was obtained from the RIKEN Cell Bank (Cell No.
RCB0987, Tsukuba, Japan). Myoblasts were cultured in growth medium consisting of high-
glucose Dulbecco’s modified Eagle’s medium (DMEM; Wako, Osaka, Japan), 10% (vol/vol)
fetal bovine serum (Equitech Bio, Kerrville, TX), 100 U/mL penicillin, and 100 μg/mL strepto-
mycin (Wako) at 37˚C in a humidified atmosphere of 5% CO2. When the cells reached 80%
confluence, the culture medium was changed to differentiation medium (DM), consisting of
high-glucose DMEM, 2% heat-inactivated horse serum (Thermo Fisher Scientific, Waltham,
MA), 100 U/mL penicillin, and 100 μg/mL streptomycin, to induce myogenesis.
C2C12 myoblasts were treated with LPS from Escherichia coli 026:B6 (Sigma Aldrich, St.
Louis, MO) dissolved in phosphate-buffered saline (PBS) at a concentration of 0.1 or 1 μg/mL
for various times between 2 h and 144 h, as indicated. MyoD and myogenin expression and
NF-κB (p65) DNA-binding activity were analyzed at 48 h, while expression of myosin heavy
chain (MyHC) II, a myogenic marker, and myostatin was measured at 144 h. The TLR4 signal-
ing inhibitor TAK-242 (Merck Millipore, Darmstadt, Germany) was added to cells at a final
concentration of 1 μg/mL in dimethyl sulfoxide (DMSO, 0.1% vol/vol) immediately after the
addition of LPS. The anti-TNF-α-neutralizing antibody (goat polyclonal, Cat. No. AB-410-
NA; R&D Systems, Minneapolis, MN) was added at 5 μg/mL in PBS at 1 h prior to the addition
of LPS. The anti-TLR2 neutralizing antibody T2.5 (mouse monoclonal, Cat. No. mab-mtlr2;
InvivoGen, San Diego, CA) was added at 10 μg/mL in PBS at 1 h prior to the addition of LPS.
The cell stimulators and inhibitors were present throughout the incubation. DM containing
the appropriate concentrations of vehicle, LPS, TAK-242, and antibodies was exchanged every
other day.
Total RNA isolation and reverse-transcription polymerase chain reaction
(RT-PCR)
Total RNA was extracted from C2C12 cells using ISOGEN (Wako) according to the manufac-
turer’s protocol. Precipitated total RNA was dissolved in diethylpyrocarbonate-treated water.
To remove contaminating genomic DNA, the samples were treated with recombinant DNase I
(Takara Bio, Kusatsu, Japan) for 15 min at 37˚C and re-precipitated. First-strand cDNA was
prepared from total RNA (1 μg) using random hexamer priming and Moloney murine leuke-
mia virus reverse transcriptase (Thermo Fisher Scientific) in a final reaction volume of 20 μL.
The cDNA was diluted 5-fold with water and used as a template for PCR analysis. Primer se-
quences for murine TLR4, glyceraldehyde 3-phosphate dehydrogenase (GAPDH), and casein
kinase 2a2 (CK2) were: TLR4 Fw: 50-CAAGAACATAGATCTGAGCTTCAACCC-30 and Rv: 50-
GCTGTCCAATAGGGAAGCTTTCTAGAG-30; GAPDH Fw: 50-ACCACAGTCCATGCCATCA
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C-30 and Rv: 50-CACCACCCTGTTGCTGTAGCC-30; and CK2 Fw: 50-GGAGGCCCTAGAT
CTTCTTG-30 and Rv: 50-CGCGTTAAGACGTTTTGATT-30. PCR was carried out with 35
amplification cycles and an annealing temperature of 58˚C using a MyCycler Thermal Cycler
(Bio-Rad Laboratories, Hercules, CA) and Taq DNA polymerase (Takara Bio). The PCR prod-
ucts were separated by 1.5% agarose gel electrophoresis and visualized by ethidium bromide
staining.
Quantitative analysis of TLR4 transcripts was performed in duplicate by real-time RT-PCR
using SYBR Premix Ex Taq (Takara Bio), reaction capillaries (Roche Diagnostics, Mannheim,
Germany), and a Light Cycler 1.5 (Roche Diagnostics). CK2 transcripts were quantified as an
internal control. Real-time RT-PCR was performed as described previously [47,48], and
included an initial denaturing step at 95˚C for 30 s; 40 cycles of denaturing at 95˚C for 5 s,
annealing at 58˚C for 10 s, and extension at 72˚C for 15 s; and a final heating step for dissocia-
tion analysis. Crossing points were determined by the second derivative maximum method
[49], and expression levels were calculated by a modified version of the standard curve method
[50] using Light Cycler software version 3.5 (Roche Diagnostics).
Histological assessment
Cells were subjected to May–Gru¨nwald and Giemsa staining to allow clear visualization of
nuclei and myotube structures for quantitative measurements. After incubation in DM for 144
h, C2C12 cells were washed in cold PBS, fixed in 100% methanol, and stained as previously
described [51] with minor modifications. Briefly, May–Gru¨nwald staining solution (Wako)
was diluted 1:3 in sodium phosphate buffer (1 mM NaH2PO4•H2O and 1 mM Na2HPO4, pH
6.0) and added to the cells for 5 min. Cells were then washed in distilled water and incubated
in Giemsa staining solution (Wako) diluted 1:10 in distilled water for 10 min. Finally, cells
were washed twice with distilled water and visualized with an inverted microscope (Olympus
CK40, Tokyo, Japan) equipped with a camera (Olympus DP21). The myogenic index [52,53]
was used as a morphological parameter of muscle differentiation. The number of nuclei in
each myotube containing3 nuclei and the total number of nuclei were counted in 5 ran-
domly selected fields per well. The myogenic index (in %) was then calculated as: ([number of
nuclei in myotubes in 5 fields] / [total number of nuclei in 5 fields] × 100) using ImageJ soft-
ware version 1.39 (National Institutes of Health, Bethesda, MD). A total of 50–60 fields from
10–12 independent experiments was evaluated for each treatment group. Myotube widths
were measured with ImageJ software using a modification of a published method [54–56]. In
brief, cells were evaluated in 5 randomly selected fields per well. The width of each myotube
containing3 nuclei was measured at 3 different points on the cell and the average width per
myotube was calculated. A total of 175–296 myotubes (50–60 fields, 10–12 independent exper-
iments) was evaluated for each treatment group.
Western blot analysis
Cells were washed twice in cold PBS and lysed in ice-cold radioimmunoprecipitation assay
buffer consisting of 50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 1% Nonidet P-40, 0.1% sodium
dodecyl sulfate, and 0.5% sodium deoxycholate supplemented with 1% protease inhibitor
cocktail (Thermo Fisher Scientific). Cell lysates were incubated on ice for 10 min, sonicated
twice for 5 s each, and centrifuged at 4˚C for 10 min at 15,000 g. The supernatants were col-
lected and protein concentrations were determined using a protein assay kit (Bio-Rad Labora-
tories) with bovine serum albumin (Wako) as a standard. Equal amounts of protein (10 μg)
per lane were resolved by 10% polyacrylamide gel electrophoresis, and proteins were trans-
ferred to a polyvinylidene difluoride membrane (Merck Millipore) using a wet transfer method
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and an XCell SureLock System (Thermo Fisher Scientific). The membrane was blocked in 5%
(wt/vol) non-fat dried milk for 1 h at room temperature and washed in PBS-Tween 20 (0.1%
vol/vol). Membranes were then incubated for 1 h at room temperature with antibodies specific
for myosin heavy chain (MyHC) II (mouse monoclonal, Cat. No. 14–6503; Affymetrix, San
Diego, CA. 1:200 dilution), MyoD (mouse monoclonal, sc-32758; Santa Cruz Biotechnology,
Santa Cruz, CA. 1:100 dilution), myogenin (mouse monoclonal, sc-12732; Santa Cruz Biotech-
nology. 1:100 dilution), myostatin (rabbit polyclonal, ab71808; Abcam, Cambridge, UK. 1:500
dilution), or β-tubulin (rabbit polyclonal, ab6046; Abcam. 1:1000 dilution). After 3 washes of
10 min each, the blots were probed with a horseradish peroxidase-conjugated secondary anti-
body (goat anti-rabbit IgG, sc-2004 [Santa Cruz Biotechnology], 1:5000 dilution; or goat anti-
mouse IgG, 62–6520 [Thermo Fisher Scientific], 1:3000 dilution) as appropriate. Densitomet-
ric analysis of protein bands was performed using ChemiDoc XRS Plus image analysis software
(Bio-Rad Laboratories).
NF-κB assay
NF-κB (p65) DNA-binding activity was determined using a TransAM enzyme-linked immu-
nosorbent assay (ELISA) kit (Active Motif, Carlsbad, CA) according to the manufacturer’s
protocol. In brief, nuclear extracts of C2C12 cells were prepared using the Nuclear Extract Kit
(Active Motif), added to the oligonucleotide-coated plate, and incubated with the NF-κB
p65-specific primary antibody (1:1000 dilution) and horseradish peroxidase-conjugated sec-
ondary antibody (1:1000 dilution) contained in the ELISA kit. After washing, the colorimetric
reaction reagents were added, and sample absorbance at 450 nm was measured in a spectro-
photometer (Multiskan GO, Thermo Fisher Scientific). The assay was performed in duplicate.
Statistical analysis
The data are presented as the means ± standard error of the mean (SEM) unless otherwise
indicated. Data were analyzed by one-way analysis of variance (ANOVA), and the treatment
groups were compared with Tukey’s post hoc test for honest significant difference. All statisti-
cal analyses were performed using IBM SPSS Statistics for Windows, version 21.0 (IBM Corp.,
Armonk, NY). A p value <0.05 was considered statistically significant.
Results
TLR4 mRNA is expressed constitutively in differentiating myoblasts
Although TLR4 is abundantly expressed in skeletal muscle of various vertebrates, including
human and mouse [39–41], its expression pattern in differentiating myoblasts is unclear. We
examined TLR4 mRNA expression at 2, 48, 92, and 144 h after induction of C2C12 differentia-
tion and found that it is expressed constitutively (Fig 1A). Quantitation of TLR4 mRNA by
real-time RT-PCR confirmed that similar levels were expressed throughout the differentiation
period (Fig 1B). Similarly, TLR4 mRNA levels did not change after culture of C2C12 cells in
DM with LPS (0.1 or 1 μg/mL) for 144 h (Fig 1C), in agreement with previous observations by
Frost et al. [43,57] and Lang et al. [41]. These results indicate that TLR4 would be expected to
be available for LPS binding throughout C2C12 myogenesis and was unaffected by the pres-
ence of LPS.
LPS inhibits myogenesis in a dose-dependent manner
To examine the effect of LPS on myogenesis, C2C12 cells were cultured in DM for 144 h in the
presence or absence of 0.1 or 1 μg/mL LPS. These concentrations were employed for
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consistency with a previous study [19] that showed that LPS induces protein breakdown via
the ubiquitin–proteasome pathway in differentiated C2C12 cells. LPS was found to inhibit the
formation of multinucleated myotubes (Fig 2A). To quantify the morphological changes, the
proportion of total nuclei that were present in myotubes was calculated (the myogenic index;
see Materials and Methods). As shown in Fig 2B, the myogenic index was significantly lower
in LPS-treated than untreated myoblasts (control, 21 ± 3%; LPS 0.1 μg/mL, 10 ± 2%; LPS
1 μg/mL, 8 ± 2%). LPS also dose-dependently decreased the average myotube width (control,
20 ± 0.4 μm; LPS 0.1 μg/mL, 15 ± 0.5 μm; LPS 1 μg/mL, 11 ± 0.3 μm; Fig 2C and 2D), in agree-
ment with earlier observations that LPS induces muscle proteolysis [19]. We also confirmed
by western blotting that LPS dose-dependently suppressed expression of the differentiation
marker MyHC II (LPS 0.1 μg/mL vs control, 44% decrease [p< 0.01]; LPS 1 μg/mL vs control,
85% decrease [p< 0.001]; Fig 2E and 2F). Thus, LPS directly inhibits C2C12 myogenesis in a
dose-dependent manner in the absence of immune cells, which are the major sources of
inflammatory cytokines.
Effect of LPS on muscle regulatory factors and NF-κB DNA-binding activity
The myogenic regulatory factors myogenin and MyoD are responsible for the induction and
maintenance of early-phase muscle differentiation [32,33]. To understand the mechanism of
LPS-induced myogenic inhibition, we examined the expression of these regulatory factors in
LPS-treated C2C12 myoblasts. As shown in Fig 3A–3C, LPS treatment for 48 h dose-dependently
Fig 1. TLR4 mRNA expression in differentiating C2C12 myoblasts. (A–C) TLR4 mRNA levels in C2C12 myoblasts cultured in DM
for 2, 48, 96, or 144 h with or without LPS. (A) Agarose gel of TLR4 and GAPDH (internal standard) mRNA levels during differentiation.
(B) Real-time RT-PCR quantification of TLR4 mRNA levels. Data were normalized to CK2 mRNA levels and the ratio in cells cultured in
DM for 2 h was set at 1.0. Data are the mean ± SEM of 3–4 independent experiments, each performed in duplicate. (C) Quantification of
TLR4 mRNA by real-time RT-PCR. C2C12 cells were cultured with the indicated concentrations of LPS for 144 h. Data were normalized
to CK2 mRNA levels and the ratio in untreated cells was set at 1.0. Data are the mean ± SEM of 3 independent experiments performed in
duplicate. In (B) and (C), P > 0.05 for all comparisons.
https://doi.org/10.1371/journal.pone.0182040.g001
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downregulated the expression of both myogenin (LPS 0.1 μg/mL vs control, 86% decrease
[p< 0.001]; LPS 1 μg/mL vs control, 92% decrease [p< 0.001]) and MyoD (LPS 0.1 μg/mL vs
control, 42% decrease [p< 0.01]; LPS 1 μg/mL vs control, 62% decrease [p< 0.001]).
We next examined whether LPS-induced inhibition of myogenesis is associated with
increased expression of myostatin, which is a critical autocrine and paracrine inhibitor of skel-
etal muscle growth and differentiation [34–36]. Indeed, myostatin expression was increased
dose dependently by incubation with LPS for 144 h (LPS 0.1 μg/mL vs control, 185% increase
[p< 0.05]; LPS 1 μg/mL vs control, 283% increase [p< 0.001]; Fig 3D and 3E).
Previous studies have suggested that NF-κB mediates both the downregulation of MyoD
and myogenin and the upregulation of myostatin [27–31,37,38]. Thus, we next evaluated NF-
κB (p65) DNA-binding activity in LPS-treated myoblasts. C2C12 nuclear extracts were pre-
pared after 48 h of LPS treatment and analyzed by ELISA. This time point was chosen for con-
venience because the LPS-containing medium was refreshed every other day. As shown in Fig
3F, LPS treatment dose-dependently increased NF-κB DNA-binding activity (LPS 0.1 μg/mL
vs control, 201% increase [p = 0.37]; LPS 1 μg/mL vs control, 417% increase [p< 0.01]). Col-
lectively, these data suggest that LPS-induced MyoD and myogenin downregulation and
myostatin upregulation is associated with increased NF-κB activity.
Fig 2. Effect of LPS on C2C12 myogenesis. (A) LPS inhibits the formation of myotubes. Myoblasts were cultured for 144 h in DM alone (control), DM
plus LPS 0.1 μg/mL, or DM plus LPS 1 μg/mL, then fixed and subjected to May–Gru¨nwald–Giemsa staining. Representative images are shown. Scale
bar = 100 μm. Arrows indicate differentiated myotubes. (B) LPS decreases the myogenic index. Cells were treated as described in (A). Data are the
mean ± SEM of 10–12 independent experiments, each examining 5 randomly selected fields (total 50–60 fields per treatment group). (C and D) LPS
induces myotube atrophy. Cells were treated as described in (A), and the distribution of myotube widths (C) and mean myotube widths (D) were
calculated. Data are the mean ± SEM of 10–12 independent experiments, each examining 5 randomly selected fields (total 175–296 myotubes from 50–
60 fields per treatment group). (E) Representative western blot probed with antibodies to MyHC II or β-tubulin (internal standard). Cells were treated as
described in (A). (F) Quantification of the data presented in (E). Data are the mean ± SEM of 13–14 independent experiments. ***p < 0.001, **p < 0.01,
###p < 0.001, ##p < 0.01 by one-way ANOVA followed by Tukey’s honest significant difference test.
https://doi.org/10.1371/journal.pone.0182040.g002
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The inhibitory effect of LPS on myogenesis is reversible
Next, we investigated whether the inhibitory effect of LPS on myogenesis was reversible. To
address this question, we adapted the methodology of Langen et al. [28], who showed that the
toxic effect of TNF-α on C2C12 myogenesis was reversible. The cells were incubated with LPS
for 48 h, washed, and cultured in fresh LPS-free DM. Myogenin expression was examined at
24 and 48 h after LPS washout. Notably, while myogenin expression was initially reduced by
LPS, it was restored after washing and removal of LPS (Fig 4A and 4B). These results demon-
strate that the inhibitory effect of LPS on myogenic differentiation is reversible, suggesting that
it is not due to a nonspecific toxic effect such as induction of cell death.
Effect of TAK-242 on LPS-induced inhibition of myogenesis
We next assessed whether pharmacological inhibition of TLR4 signaling can ameliorate the
harmful effect of LPS on C2C12 myogenesis. Myoblasts were incubated for 144 h in the pres-
ence or absence of LPS (1 μg/mL) and/or TAK-242 (1 μM), a small molecule specific inhibitor
of TLR4 signaling [58,59]. This concentration of TAK-242 was previously found to have a ben-
eficial effect on LPS-induced insulin resistance in L6 myoblast cells [60] and primary human
skeletal muscle cells [61]. We found that TAK-242 increased the abundance of multinuclear
myotubes in LPS-treated C2C12 cells (myogenic index: LPS 1 μg/mL, 7 ± 2% vs LPS 1 μg/mL
+ TAK-242 1 μM, 13 ± 2%, p < 0.05; Fig 5A and 5B) as well as myotube width (LPS 1 μg/mL,
Fig 3. Effect of LPS on muscle regulatory factors and NF-κB activity in differentiating myoblasts. (A) LPS downregulates expression of
the positive myogenic regulatory factors myogenin and MyoD in a dose-dependent manner. C2C12 myoblasts were incubated in DM with or
without LPS (0.1 or 1 μg/mL) for 48 h. A representative western blot probed with antibodies to myogenin, MyoD, or β-tubulin (internal standard)
is shown. (B and C) Quantification of the data presented in (A). Data are the mean ± SEM of 6–7 independent experiments. (D) LPS upregulates
expression of the negative myogenic regulatory factor myostatin in a dose-dependent manner. C2C12 myoblasts were treated for 144 h as
described in (A). A representative western blot probed with antibodies to myostatin or β-tubulin (internal standard) is shown. (E) Quantification of
the data presented in (D). Data are the mean ± SEM of 14 independent experiments. (F) LPS increases NF-κB DNA-binding activity in a dose-
dependent manner. C2C12 myoblasts were incubated in DM with or without LPS (0.1 or 1 μg/mL) for 48 h, and NF-κB activity was analyzed
using a TransAM ELISA kit. Data are the mean ± SEM of 5 independent experiments performed in duplicate. ***p < 0.001, **p < 0.01,
*p < 0.05, #p < 0.05 by one-way ANOVA followed by Tukey’s honest significant difference test.
https://doi.org/10.1371/journal.pone.0182040.g003
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11 ± 0.3 μm vs LPS 1 μg/mL + TAK-242 1 μM, 16 ± 0.4 μm, p< 0.001; Fig 5C and 5D). More-
over, TAK-242 partially restored MyHC II expression (LPS 1 μg/mL + TAK-242 1 μM vs LPS
1 μg/mL, 251% increase, p < 0.05; Fig 5E and 5F), confirming its beneficial effect. Higher
TAK242 concentrations (10 μM and 100 μM) did not further improve myogenesis and, in fact,
were toxic to the cells (data not shown). Collectively, these results indicate that TLR4 signaling
is responsible, at least in part, for the inhibition of myogenesis by LPS, since TAK-242 treat-
ment attenuated the effect.
TLR4–NF-κB signaling mediates LPS-induced dysregulation of muscle
regulatory factors
Next, we evaluated whether TLR4 signaling mediates the LPS-induced perturbation of muscle
regulatory factors. As shown in Fig 6A–6C, co-administration of TAK-242 (1 μM) partially
reversed the LPS-induced decrease in expression of myogenin (LPS 1 μg/mL + TAK-242 1 μM
Fig 4. LPS-induced inhibition of myogenin expression is reversible. C2C12 cells were cultured in DM with or without LPS
(1 μg/mL) for 48 h, washed free of LPS, and then cultured for an additional 24 h (72 h total) or 48 h (96 h total) in fresh DM. (A)
Representative western blot probed with antibodies to myogenin or β-tubulin (internal standard). (B) Quantification of the data
presented in (A). Data are the mean ± SEM of 5 independent experiments. ***p < 0.001,*p < 0.05, #p < 0.05, ##p < 0.01 by one-
way ANOVA followed by Tukey’s honest significant difference test.
https://doi.org/10.1371/journal.pone.0182040.g004
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vs LPS 1 μg/mL, 251% increase; p< 0.05) but not of MyoD (101% increase, p = 1.0). Similarly,
LPS-induced upregulation of myostatin was partially blocked by TAK-242 (30% decrease vs
LPS 1 μg/mL, p< 0.05; Fig 6D and 6E). However, at 0.1 μg/mL LPS, TAK-242 failed to rescue
the upregulation of myostatin expression (5% decrease, p = 0.7). TAK-242 also decreased NF-
κB DNA-binding activity in LPS-treated myoblasts (48% decrease vs LPS 1 μg/mL, p< 0.05;
Fig 6F). These data therefore suggest that TLR4 acts as an upstream regulator of NF-κB-medi-
ated dysregulation of myogenic regulatory factors.
LPS signals through both TLR2 and TLR4 to activate NF-κB
As demonstrated in Fig 5 and Fig 6, selective inhibition of TLR4 signaling did not fully sup-
press LPS-induced NF-κB activation and dysregulation of muscle regulatory factors. Since LPS
is also a ligand for TLR2 [62–64], and TLR2 mRNA is expressed in C2C12 myoblasts [41,43],
we considered that LPS might be signaling through both TLR2 and TLR4. To examine this,
myoblasts were incubated with 1 μg/mL LPS in the presence or absence of a TLR2-neutralizing
antibody (T2.5, 10 μg/mL), and NF-κB activity was measured after 48 h. This concentration of
anti-TLR2 antibody was previously found to prevent serum amyloid A-induced TLR2-depen-
dent signaling in C2C12 myotubes [56]. As shown in Fig 7A, addition of anti-TLR2 decreased
Fig 5. Effect of TAK-242 on LPS-induced inhibition of myogenesis. (A) May–Gru¨nwald–Giemsa staining of C2C12 cells cultured for 144 h in DM
alone, DM plus LPS (1 μg/mL), or DM plus LPS (1 μg/mL) and TAK-242 (1 μM). Representative images are shown. Scale bar = 100 μm. Arrows
indicate differentiated myotubes. (B) TAK-242 partially reversed the LPS-induced decrease in myogenic index. Cells were treated as described in
(A). Data are the mean ± SEM of 10 independent experiments per treatment group, each examining 5 randomly selected fields (total 50 fields). (C
and D) TAK-242 partially ameliorated the LPS-induced myotube atrophy. Cells were treated as described in (A), and the distribution of myotube
widths (C) and mean myotube widths (D) were calculated for each treatment group. Data are the mean ± SEM of 10–12 independent experiments,
each examining 5 randomly selected fields (total 194–296 myotubes from 50–60 fields per treatment group). (E) Representative western blot probed
with antibodies to MyHC II or β-tubulin (internal standard). Cells were treated as described in (A). (F) Quantification of the data presented in (E). Data
are the mean ± SEM of 12–13 independent experiments. ***p < 0.001, ###p < 0.001, #p < 0.05 by one-way ANOVA followed by Tukey’s honest
significant difference test.
https://doi.org/10.1371/journal.pone.0182040.g005
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LPS-induced NF-κB activation by about 30%, although the difference did not reach the level of
statistical significance (p = 0.62). The selective TLR4 inhibitor had a greater effect on NF-κB
activity (Fig 7B), suggesting that LPS signals predominantly through TLR4 but at least partially
through TLR2 in these cells, This could be one possible explanation for the failure of TAK-242
to completely suppress the LPS-induced effects on NF-κB and myogenic regulatory factors.
Myoblast-derived autocrine/paracrine TNF-α is involved in LPS-induced
inhibition of myogenesis
There is considerable evidence that LPS regulates the expression of proinflammatory cyto-
kines, such as TNF-α and interleukin 6, in mouse myoblasts and skeletal muscle [40,41,43],
and TNF-α has previously been shown to inhibit myogenic differentiation [27–31]. Therefore,
we hypothesized that myoblast-derived TNF-α may be involved in LPS-induced inhibition of
myogenesis. To test this hypothesis, we examined C2C12 cells after treatment with LPS (1 μg/
mL) in the absence or presence of a TNF-α-neutralizing antibody (5 μg/mL). This concentra-
tion of antibody was previously shown to inhibit TNF-α secretion and subsequent NF-κB
activation induced by serum restriction of C2C12 myoblasts [65]. We found that the TNF-α-
neutralizing antibody partially but significantly reversed the LPS-induced downregulation of
myogenin (LPS + anti-TNF-α vs LPS, 255% increase, p< 0.05; Fig 8A and 8B), MyoD (179%
Fig 6. Effect of TAK-242 on LPS-induced perturbation of muscle regulatory factors and NF-κB activity. (A) TAK-242 partially reverses
the LPS-induced downregulation of myogenin, but not of MyoD. C2C12 myoblasts were cultured for 48 h in DM alone, with LPS (1 μg/mL or
0.1 μg/mL), or with a combination of LPS (1 μg/mL) and TAK-242 (1 μM). A representative western blot probed with antibodies to myogenin,
MyoD, or β-tubulin (internal standard) is shown. (B and C) Quantification of the data presented in (A). Data are the mean ± SEM of 5–7
independent experiments. (D) TAK-242 partially reverses the LPS-induced upregulation of myostatin expression. C2C12 myoblasts were
cultured for 144 h as described in (A). A representative western blot probed with antibodies to myostatin or β-tubulin (internal standard) is
shown. (E) Quantification of the data presented in (D). Data are the mean ± SEM of 14–16 independent experiments. (F) TAK-242 inhibits
NF-κB activity in LPS-treated differentiating myoblasts. Cells were treated as described in (A), and NF-κB activity was analyzed using a
TransAM ELISA kit. Data are the mean ± SEM of 5 independent experiments performed in duplicate. ***p < 0.001, *p < 0.05, #p < 0.05 by
one-way ANOVA followed by Tukey’s honest significant difference test.
https://doi.org/10.1371/journal.pone.0182040.g006
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increase, p< 0.001; Fig 8A and 8C), and MyHC II (262% increase, p< 0.01; Fig 8D and 8E)
expression, and additionally suppressed the LPS-induced upregulation of myostatin expres-
sion (40% decrease, p< 0.01; Fig 8D and 8F) and NF-κB activation (40% decrease, p< 0.05;
Fig 8G). These results suggest that NF-κB activation and subsequent effects on myogenic regu-
latory factors induced by LPS are partially mediated by myoblast-derived TNF-α. Thus, it is
possible that such an autocrine/paracrine TNF-α loop is involved in the impairment of muscle
regeneration.
Based on these collective data, we propose a mechanistic model for the inhibition myogen-
esis by LPS in differentiating myoblasts (Fig 9).
Discussion
In the present study, we found that LPS inhibits C2C12 myogenesis through the TLR4–NF-κB
and autocrine/paracrine TNF-α-mediated pathways. We found that LPS downregulated
MyoD and myogenin expression and upregulated myostatin expression in a dose-dependent
manner. Both pharmacological inhibition of TLR4 signaling and antibody-mediated neutrali-
zation of TNF-α reduced NF-κB activity and attenuated the LPS-induced dysregulation of
muscle regulatory factors.
For our in vitro experiments, we employed two concentrations of LPS, 0.1 and 1 μg/mL,
and observed a dose-dependent inhibitory effect on murine myoblast differentiation. A previ-
ous study suggested that humans were more than 10,000-fold more sensitive than mice to LPS
[66], raising the possibility that human muscle regeneration could be much more vulnerable
Fig 7. Effect of a TLR2-neutralizing antibody on NF-κB activity in LPS-treated myoblasts. (A) C2C12 myoblasts were cultured for 48 h in DM
alone, LPS (1 μg/mL), or LPS (1 μg/mL) plus TLR2-neutralizing antibody (10 μg/mL). Data are the mean ± SEM of 7 independent experiments
performed in duplicate. (B) C2C12 myoblasts were cultured for 48 h in DM with LPS (1 μg/mL), LPS (1 μg/mL) plus TAK-242 (1 μM), or LPS (1 μg/
mL) plus TLR2-neutralizing antibody (10 μg/mL). NF-κB activity was measured by ELISA. Data are the mean ± SEM of 7–10 independent
experiments performed in duplicate. **p < 0.01, *p < 0.05 by one-way ANOVA followed by Tukey’s honest significant difference test.
https://doi.org/10.1371/journal.pone.0182040.g007
Lipopolysaccharide inhibits myogenic differentiation of C2C12 myoblasts
PLOS ONE | https://doi.org/10.1371/journal.pone.0182040 July 24, 2017 12 / 22
Fig 8. Effect of a TNF-α-neutralizing antibody on LPS-induced perturbation of muscle differentiation.
(A) C2C12 myoblasts were cultured for 48 h in DM alone, LPS (1 μg/mL), or LPS (1 μg/mL) plus TNF-α-
neutralizing antibody (5 μg/mL). A representative western blot probed with antibodies to myogenin, MyoD, or
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to the effects of LPS. Circulating LPS levels are commonly elevated in conditions such as sepsis
[4] and endogenous diseases [5–15], and muscle atrophy can also be observed in these condi-
tions [16]. Therefore, LPS-induced derangement of myogenesis might be a cause of muscle
wasting in patients with sepsis or metabolic endotoxemia.
In this study, we demonstrated that the TLR4 signaling pathway mediated LPS-induced
activation of NF-κB, downregulation of MyoD and myogenin expression, and upregulation of
myostatin expression. Our findings are in agreement with several earlier observations that
exogenous TNF-α-induced activation of NF-κB inhibited myogenesis in C2C12 cells by sup-
pressing MyoD and myogenin expression [27–31]. NF-κB-mediated upregulation of myosta-
tin has also been observed in other model systems, such as H2O2-treated cultured myoblasts
[38] and mouse models of liver cirrhosis and hyperammonemia [37]. In contrast, several
studies have suggested that myostatin expression in skeletal muscle is not increased in sepsis
models. For example, Smith et al. observed that myostatin mRNA levels were reduced and
myostatin protein levels were unchanged in rat skeletal muscle 16 h after cecal ligation and
puncture [67]. Lang et al. reported that myostatin mRNA was not increased 24 h after LPS
administration to rats [68]. One possible explanation for this discrepancy is the shorter endo-
toxin exposure times, since we observed increased myostatin expression in C2C12 cells after
144 h of LPS treatment. Martin et al. noted a time-dependent increase in myostatin mRNA
expression after administration of LPS to mice; they found that the levels remained unchanged
β-tubulin (internal standard) is shown. (B and C) Quantification of the data presented in (A). Data are the
mean ± SEM of 7–15 independent experiments. (D) C2C12 myoblasts were cultured for 144 h as described in
(A). A representative western blot probed with antibodies to MyHC II, myostatin, or β-tubulin (internal
standard) is shown. (E and F) Quantification of the data presented in (D). Data are the mean ± SEM of 5–21
independent experiments. (G) Cells were treated as described in (A), and NF-κB activity was analyzed by
ELISA. Data are the mean ± SEM of 7 independent experiments performed in duplicate. ***p < 0.001,
**p < 0.01, *p < 0.05, ###p < 0.001, ##p < 0.01, #p < 0.05 by one-way ANOVA followed by Tukey’s honest
significant difference test.
https://doi.org/10.1371/journal.pone.0182040.g008
Fig 9. Proposed mechanism of LPS inhibition of myogenesis in differentiating myoblasts.
https://doi.org/10.1371/journal.pone.0182040.g009
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at 24 h after LPS injection but increased significantly after 76 h [69]. In the clinical setting, sep-
sis survivors often display systemic inflammation for protracted periods and also develop mus-
cle wasting. Circulating myostatin is commonly elevated in patients with conditions such as
chronic liver and kidney disease [25,37,70], diabetes mellitus [71], and human immunodefi-
ciency virus infection [72], and in the elderly [73,74]. All of these populations are likely to be
chronically exposed to LPS due to bacterial translocation [15]. Taken together, these findings
suggest that persistent exposure to LPS or inflammation may be required to induce myostatin.
We found that myogenin expression was rapidly restored after switching from LPS (1 μg/
mL)-containing medium to fresh medium, suggesting that the inhibition of myogenesis was
reversible and not simply a toxic effect of LPS, such as induction of apoptosis. Shang et al.
examined C2C12 cell viability after exposure to various concentrations of LPS [75]. They
found that LPS at 1–10 μg/mL had no effect on C1C12 apoptosis, whereas higher concentra-
tions (100–150 μg/mL) induced apoptosis through caspase-3 activation. Our findings are thus
consistent with their data. Reversible inhibition of myogenesis has also been observed upon
treatment of C2C12 myoblasts with TNF-α [28]. Taken together, these data suggest that persis-
tent NF-κB activation may be required to block myogenesis and promote muscle wasting.
While the role of TLR4 in innate immunity is well characterized, its role in skeletal muscle
development has been unclear. To address this knowledge gap, we examined the effect of a
selective TLR4 signaling pathway inhibitor on the LPS-induced events. We observed that
TAK-242 partially rescued the LPS-induced inhibition of myogenesis, activation of NF-κB,
downregulation of myogenin, and upregulation of myostatin, suggesting that TLR4 is an
upstream regulator of skeletal muscle myogenesis. Previous studies have suggested that TLR4
plays an important role in muscle protein breakdown. Doyle et al. [19] found that TLR4-me-
diated LPS signaling induced muscle catabolism via coordinate activation of the ubiquitin–
proteasome and autophagy pathways. According to Dehoux et al. [20] and Martin et al. [69],
ubiquitin ligase mRNA expression was induced in both rat and mouse skeletal muscle after
LPS injection. In agreement with these findings, we observed that LPS dose-dependently
decreased the myotube width, and that inhibition of TLR4 signaling prevented the atrophy.
Collectively, these findings indicate that LPS may induce muscle wasting via synergistic effects
on myogenesis and muscle proteolysis through TLR4. Skeletal muscle TLR4 is upregulated in
diabetic and obese subjects [76] as well as in the elderly [5,77], suggesting that the TLR4–NF-
κB pathway may be elevated in these populations. Thus, inhibition of the TLR4 signaling axis
might be a useful method for preventing or reversing LPS-induced muscle wasting in patients
with sepsis or metabolic endotoxemia. Future studies should address the effects of TLR4 antag-
onists on LPS-induced muscle breakdown.
We found that antibody-mediated neutralization of TNF-α reduced the LPS-induced
increase in NF-κB DNA-binding activity, downregulation of myogenin and MyoD, and upre-
gulation of myostatin in C2C12 cells, suggesting that LPS-induced autocrine/paracrine TNF-α
might be involved in the impairment of muscle regeneration. Autocrine/paracrine regulation
of TNF-α has also been observed in C2C12 myoblasts following serum restriction [65] and in
various other cell lines and tissues, including cancer cells [46,78], immune cells [79,80], and
microglia [81]. In skeletal muscle myoblasts, TNF-α is a strong activator of NF-κB [65] and of
its own synthesis [82]. Therefore, as is the case in cancer cells [46,78], a positive TNF-α auto-
crine/paracrine loop in response to LPS may lead to persistent NF-κB activation in myoblasts,
further inhibiting myogenesis and thus inducing muscle wasting.
Interestingly, we found that TNF-α neutralization, but not TLR4 inhibition by TAK-242,
reversed the LPS-induced inhibition of MyoD expression. We speculate that MyoD expression
might be more sensitive to regulation by TNF-α than by TLR4 signaling. In support of this
possibility, the pattern of NF-κB activation by LPS and TNF-α has been shown to differ. In
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C2C12 myotubes, TNF-α was found to persistently activate NF-κB in a biphasic manner,
while LPS did not [31]. Moreover, in human epithelial cells, LPS from Haemophilus influenzae
(exogenous activation) and TNF-α (endogenous activation) synergistically induced NF-κB
activation via two distinct signaling pathways [83]. In addition to the involvement of TLR2
mediated signaling, this could be another explanation for the failure of TAK-242 to fully ame-
liorate the harmful effect of LPS on differentiating myoblasts.
In vivo, LPS induces circulating immune cells to produce copious amounts of inflammatory
cytokines, which have been implicated as potential mediators of muscle wasting via inhibition
of myogenesis [27–31] and acceleration of muscle proteolysis [18,84,85]. In fact, inflammatory
cytokine concentrations are elevated in the circulation of patients with sepsis [86] and meta-
bolic endotoxemia [87–89]. Our study extends these observations by demonstrating that LPS
itself can directly inhibit myogenesis through TLR4–NF-κB signaling and myoblast-derived
TNF-α. Systemic and local inflammatory reactions may synergize to induce muscular wasting.
In this study, cells were co-incubated with TAK-242 dissolved in DMSO (final concentra-
tion 0.1% [vol/vol]) and LPS dissolved in PBS. We acknowledge that a DMSO vehicle control
was not included in two experiments shown in Figs 5 and 6. High concentrations of DMSO
(1–2% [vol/vol]) have been shown to augment the LPS effect on immune cells (i.e., increase
inflammatory cytokine secretion) [90]; therefore, in our study, the relative effect of TAK-242
on the LPS response may have been weakened. Nevertheless, previous studies have shown
that, even at concentrations as high as 1–2% (vol/vol), DMSO has no effect on NF-κB activity
in various cell lines, reducing this concern [90–92].
We observed that TAK-242 significantly decreased myostatin expression when cells were
stimulated with LPS at 1 μg/mL (30% decrease, p < 0.05) but not at 0.1 μg/mL (5% decrease,
p = 0.7). At present, we do not have a plausible explanation for this discrepancy.
To date, no drugs have been approved for the treatment of skeletal muscle wasting. Our
finding that blockade of the TLR4–NF-κB pathway or TNF-α can reverse impaired myogen-
esis suggests a new set of drug targets for clinical intervention in sepsis- or metabolic endotox-
emia-induced muscle debilitation. Clinical trials with a TLR4 antagonist [93–95] and TNF-α
inhibitor [96] have shown no improvement of the mortality rate of severe sepsis patients; how-
ever, those trials did not examine long-term muscle function [93–96]. The results presented
here provide a rationale to test the effects of TLR4 and TNF-α antagonists on LPS-induced
muscle wasting in sepsis or metabolic endotoxemia patients. Our data should also stimulate
further studies to clarify the role of TLR4–NF-κB and TNF-α signaling in muscle wasting.
Conclusions
LPS inhibits C2C12 myogenesis by dose-dependently downregulating myogenin and MyoD
expression and upregulating myostatin expression. TAK-242, a selective inhibitor of
TLR4-mediated signaling, and a TNF-α-neutralizing antibody both reduced NF-κB activity
and attenuated the downregulation of myogenic regulatory factors and upregulation of myos-
tatin in LPS-treated C2C12 myoblasts. Consequently, myogenesis was partially restored. These
data suggest that LPS inhibits myogenic differentiation of skeletal muscle myoblasts through
TLR4–NF-κB signaling and myoblast-derived autocrine/paracrine TNF-α, raising the possibil-
ity that these pathways also contribute to the development of muscle wasting in patients with
sepsis or metabolic endotoxemia.
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